Background: Temporary prophylactic pancreatic duct stenting effectively reduces post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk patients, but the optimal stent remains unclear. We compared rate of spontaneous passage, and technical difficulty of placement for 3-Fr and 5-Fr stents.
Methods: A randomized controlled trial at a single academic medical center. Patients deemed high risk for PEP randomly received 5-Fr or 3-Fr pancreatic duct stents. Primary outcome was spontaneous stent passage by 2 weeks. Secondary outcomes were ease and time for stent placement, and number of guide wires required for the entire procedure.
Results: Patients (69 female [89 %]; mean age 44.9 years, standard deviation [SD] 16.8) were randomly assigned to receive 5-Fr (n = 38) and 3-Fr (n = 40) stents. Indications for stenting were similar. Seven patients in the 3-Fr group actually received a 5-Fr stent, and two in the 5-Fr group had a 3-Fr stent. Spontaneous passage or non-passage was confirmed in 64 (83 %). No statistically significant difference in spontaneous passage rates was seen (5-Fr group, 68.4 %; 3-Fr group 75.0 %; P = 0.617). Non-passage rates were 10.5 % (5-Fr group) and 10.0 % (3-Fr group) (P = 1.00). The study was stopped after a futility analysis for the primary end point. Placement of 5-Fr stents was rated easier, at a mean score of 1.8 (5-Fr) vs. 3.4 (3-Fr), P < 0.001, with a trend towards being faster, 9.2 vs. 11.1 minutes (P = 0.355). Fewer guide wires were required for 5-Fr stent placement, 1.5 vs. 1.9 (P = 0.002). PEP rates did not differ (P = 0.519).
Conclusion: Placement of 5-Fr compared to 3-Fr pancreatic duct stents for PEP prophylaxis is easier, faster, and requires fewer wires. No statistically significant difference in spontaneous passage was found between the two sizes.
References
1
Cotton P B, Lehman G, Vennes J. et al .
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
Gastrointest Endosc.
1991;
37
383-393
2
Fazel A, Quadri A, Catalano M F. et al .
Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study.
Gastrointest Endosc.
2003;
57
291-294
3
Singh P, Das A, Isenberg G. et al .
Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials.
Gastrointest Endosc.
2004;
60
544-550
4
Aizawa T, Ueno N.
Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones.
Gastrointest Endosc.
2001;
54
209-213
5
Smithline A, Silverman W, Rogers D. et al .
Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients.
Gastrointest Endosc.
1993;
39
652-657
6
Tarnasky P R, Palesch Y Y, Cunningham J T. et al .
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.
Gastroenterology.
1998;
115
1518-1524
7
Das A, Singh P, Sivak Jr. M V, Chak A.
Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis.
Gastrointest Endosc.
2007;
65
960-968
8
Smith M T, Sherman S, Ikenberry S O. et al .
Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy.
Gastrointest Endosc.
1996;
44
268-275
9
Rashdan A, Fogel E L, McHenry Jr. L. et al .
Improved stent characteristics for prophylaxis of post-ERCP pancreatitis.
Clin Gastroenterol Hepatol.
2004;
2
322-329
10
Chahal P, Tarnasky P R, Petersen B T. et al .
Short 5Fr vs long 3Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis.
Clin Gastroenterol Hepatol.
2009;
7
834-839
11
Freeman M L, Overby C, Qi D.
Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success.
Gastrointest Endosc.
2004;
59
8-14
12
Komorita S S.
Attitude content, intensity, and the neutral point on a Likert scale.
J Soc Psychol.
1963;
61
327-334
13
Likert R.
A technique for the measurement of attitudes.
Arch Psychol.
1932;
140
1-55
14
Mallery J S, Baron T H, Dominitz J A. et al .
Complications of ERCP.
Gastrointest Endosc.
2003;
57
633-638
15
Cotton P B, Vennes J, Geenen J E. et al .
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
Gastrointest Endosc.
1991;
37
383-393
16
Spiegelhalter D J, Freedman L S, Blackburn P R.
Monitoring clinical trials: conditional or predictive power?.
Control Clin Trials.
1986;
7
8-17
17
Masci E, Mariani A, Curioni S, Testoni P A.
Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis.
Endoscopy.
2003;
35
830-834
18
Aronson N, Flamm C R, Bohn R L. et al .
Evidence-based assessment: patient, procedure, or operator factors associated with ERCP complications.
Gastrointest Endosc.
2002;
56 (Suppl. 6)
S294-S302
19
Harewood G C, Pochron N L, Gostout C J.
Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla.
Gastrointest Endosc.
2005;
62
367-370
20
Derfus G A, Hogan W J.
Effects of endoscopic pancreatic duct stent placement on pancreatic ductal morphology [abstract].
Gastrointest Endosc.
1990;
36
(206A)
E. ZolotarevskyMD
University of Michigan Division of Gastroenterology
3912 Taubman Center Drive 1500 East Medical Center Drive Ann Arbor, MI 48109
Fax: +1-734-936-7392
Email: ezolotar@med.umich.edu